Genmab — Maj 2019
-
Doctor survey suggests 'rapid uptake' for Horizon's teprotumumab, says Jefferies Jefferies analyst David Steinberg says his survey of 25 high-volume physicians regarding the treatment landscape for thyroid eye disease indicates the potential for rapid uptake of Horizon Pharma's teprotumumab.
-
The responses suggest not only high unmet need for this rare condition but also a "unanimous view" that teprotumumab is disease modifying, Steinberg tells investors in a research note. He believes the antibody could be priced at a premium to his $100,000 per treatment forecast, assuming approval in the first half of 2020. Steinberg keeps a Buy rating on Horizon Pharma with a $34 price targe
https://thefly.com/landingPageNews.php?id=2913164 -
Enapotamab Vedotin (HuMax-AXL-ADC) trial enlarged from 292 to 374 patients (extra cohorts being added i assume, as expected) https://clinicaltrials.gov/ct2/history/NCT02988817?A=12&B=13&C=merged#StudyPageTop
-
Was this expected? Thats about 80 DKK more to run this ekstra cohort
-
80 mill DKK
-
Third Quarter Update
• September: Based on encouraging signs of early activity, one of the lung cancer cohorts in the
ongoing Phase I/II study of enapotamab vedotin will be expanded. In addition, cohorts in mixed
solid tumors and ovarian cancer are being added to the study. -
God morgen
-
God morgen.
-
God morgen
-
Er Nordnet nede?
-
Sorry..Det er min lånte labtop som driller.
-
A tuff year for many Genmab-investors.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind